Remicade (infliximab) - J&J
Bimzelx (bimekizumab-bkzx) - UCB
Cimzia (certolizumab pegol) - Astellas, UCB
Humira (adalimumab) - AbbVie
Tremfya (guselkumab) - J&J
tofacitinib - Generic mfg.
methotrexate - Generic mfg.
cyclosporin A microemulsion - Generic mfg.
Cosentyx (secukinumab) - Novartis
sulfasalazine - Generic mfg.
Stelara (ustekinumab) - J&J
leflunomide - Generic mfg.
Simponi (golimumab) - J&J
Rinvoq (upadacitinib) - AbbVie
azathioprine - Generic mfg.
Enbrel (etanercept) - Pfizer, Amgen
Real-world effectiveness of Bimekizumab in refractory uveitis associated with spondyloarthritis: a multicenter study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #693; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Baseline uveitis characteristics and prior treatments before bimekizumab Abbreviations (alphabetical order) : ADA: adalimumab; AS: ankylosing spondylitis; AZA: azathioprine; BKZ: bimekizumab; CZP: certolizumab; Cyclosporine: cyclosporine A; ETN: etanercept; GOLI: golimumab; GUSEL: guselkumab; IFX: infliximab; LEF: leflunomide; MTX: methotrexate; nr axSpA: non radiographic axial spondyloarthritis; PsA: psoriatic arthritis; SECU: secukinumab; SSZ: sulfasalazine; TOFA: tofacitinib; UPA: upadacitinib; USTE: ustekinumab. In this real‑world multicenter study, BKZ was associated with a marked reduction in recurrent AU flares in patients with axSpA or PsA and refractory uveitis, regardless of prior biologic or targeted synthetic therapy failures. Dual IL‑17A/IL‑17F inhibition may offer advantages over selective IL‑17A blockade in this setting. Table." 
Clinical • Real-world • Real-world effectiveness • Real-world evidence • Ankylosing Spondylitis • Axial Spondyloarthritis • Candidiasis • Immunology • Infectious Disease • Inflammatory Arthritis • Ocular Inflammation • Ophthalmology • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis • Uveitis
https://acrabstracts.org/abstract/real-world-effectiveness-of-bimekizumab-in-refractory-uveitis-associated-with-spondyloarthritis-a-multicenter-study/
 
CARMEN SECADA-GÓMEZ1; José Luis Martin-Varillas2; Marta Garijo Bufort3; Angel Garcia-Aparicio4; Virginia villaverde5; Ana Urruticoechea-Arana6; Olga Maiz7; MONICA DELGADO SANCHEZ8; Diana peiteado López9; Vanesa Hernández-Hernández10; Àngels Martínez-Ferrer11; Verónica Pérez Guijo12; Alba Belmonte-Mora13; Maria Luisa Gonzalez-Gomez14; Balbina Carmen Gonzalez Alvarez15; Elena de la Mata16; Marina Pavía-Pascual17; Lilyan Consuelo Charca Benavente18; Kamran Naraghi19; Helena Marzo-Ortega20; Montserrat Robustillo Villarino21; Emma Beltrán Catalán22; Leticia Lojo-Oliveira23; Vicente Aldasoro Caceres24; Oscar Fontsere25; Sergio Rodríguez26; Juan Ramón De Dios27; Javier Manzaneque Sánchez28; Lara Mendez Diaz29; Laura Álvarez Ortiz30; Paloma Figueras González31; Amalia Rueda Cid32; Sara Alonso33; Ruben Queiro34; Laura Blanco Ramis35; Manuel Pujol Busquets36; Mireia Moreno37; Ricardo Blanco38
 
Sep 8, 2026
 
Prev Next